Attached files
| file | filename |
|---|---|
| 8-K/A - 8-K AMENDMENT NO 1 - Eledon Pharmaceuticals, Inc. | d79037d8ka.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
| • | Registration Statement (Form S-1 No. 333-237397) of Novus Therapeutics, Inc.; |
| • | Registration Statement (Form S-1 No. 333-232011) of Novus Therapeutics, Inc.; |
| • | Registration Statement (Form S-3 Nos. 333-226286 and 333-218949) of Novus Therapeutics, Inc.; |
| • | Registration Statement (Form S-8 No. 333-232428) pertaining to the Novus Therapeutics, Inc. 2014 Stock Incentive Plan, Novus Therapeutics, Inc. 2014 Employee Stock Purchase Plan, and Stand Alone Inducement Stock Options of Novus Therapeutics, Inc.; |
| • | Registration Statement (Form S-8 No. 333-216432 and No. 333-200413) pertaining to the 2014 Stock Incentive Plan and 2014 Employee Stock Purchase Plan of Tokai Pharmaceuticals, Inc.; |
| • | Registration Statement (Form S-8 Nos. 333-210058 and 333-203032) pertaining to 2014 Stock Incentive Plan of Tokai Pharmaceuticals, Inc.; and |
| • | Registration Statement (Form S-8 No. 333-237380) pertaining to the 2007 Stock Incentive Plan, Novus Therapeutics, Inc. 2014 Stock Incentive Plan and Novus Therapeutics, Inc. 2014 Employee Stock Purchase Plan |
of our report dated May 15, 2020, with respect to the financial statements of Anelixis Therapeutics, Inc. for the years ended December 31, 2019 and 2018, incorporated by reference in Form 8-K/A and included in Schedule 14A, Annex B of the Proxy Statement, of Novus Therapeutics, Inc.
AAFCPAs, Inc
Boston, Massachusetts
November 20, 2020